Magnasense Investor Relations Material
Latest events
Q4 2024
5 Mar, 2025
Q3 2024
15 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Magnasense
Access all reports
Magnasense, a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. Magnasense's main product is the Oncolynx®, a urine test to be used with treatment of colorectal cancer patients. The test measures the levels of the drug in the bloodstream. This helps physicians optimize the dosage to achieve effective and safe treatment of cancer with biological drugs. The company was incorporated in 2019 and is based in Lund, Sweden.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
MAGNA
Country
🇸🇪 Sweden